Dublin, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Multiple Myeloma Pricing, Reimbursement, and Access" report to their offering. Growth in the multiple myeloma market will be spurred by the approval of novel drugs and the increasing role of combination therapy, but risk-sharing agreements will be key to entry into increasingly restrictive markets. This report addresses the following questions: - How do access restrictions for multiple myeloma drugs differ across markets and why? - Which clinical trial comparators and outcomes are necessary for approval and uptake in each market? - What impact, if any, will value assessment tools have on US reimbursement patterns? - When and where are risk-sharing agreements useful in gaining market access? - What are US and EU payers' and physicians' opinions on monoclonal antibodies Darzalex and Empliciti? - What effect will generic bortezomib have on the pricing and reimbursement of multiple myeloma drugs in the US and EU markets? Key Topics Covered: EXECUTIVE SUMMARY MARKET CONTEXT - Novel therapies and combinations will increase the budget impact of multiple myeloma and the life expectancy of patients - spuring new restrictions and risk-sharing measures - Marketed multiple myeloma products in the US, Japan, and five major EU markets - Pipeline multiple myeloma treatments in late-stage development - Bibliography GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS - Insights and strategic recommendations - Payer archetypes and trends in access - Growing expenditure may trigger more restrictive access - Endpoints and magnitude effect - New drugs may fit into the growing role of maintenance therapy - The impact of generic Velcade - Bibliography US PRICING - Use of combination therapy and longer treatment durations pushing up costs in multiple Myeloma - Monoclonal antibodies prove costly, but affordability increases with sustained responses - Pricing trends in the US look toward greater cost control - Bibliography US PAYER AND KEY OPINION LEADER INSIGHTS - Insights and strategic recommendations - Insurers commonly reimburse NCCN-backed off-label and payer-restricted indications - Oncologists: heightened restrictions unlikely for multiple myeloma medicines in near future - Bibliography US REIMBURSEMENT - Insights and strategic recommendations - NCCN guidelines heavily feature Revlimid, Thalomid, and Velcade - Drug value frameworks will guide the formation of clinical pathways and reimbursement criteria in the future - Payers have limited utilization management options despite rising costs, but oncology pathways are making inroads - Oral multiple myeloma therapies are found in the top tier of most commercial formularies and all Medicare formularies - Prior authorization criteria follow FDA labels - Revlimid dominates the multiple myeloma market, used in combination with most new agents - Patient assistance programs look to improve access by relieving out-of-pocket costs, 28.Kyprolis gaining ground in earlier indications with enhanced efficacy - Pomalyst is likely superior to Revlimid, but is set to be left for use in later lines of therapy - New drugs must display superiority over future generic competition - Numerous drugs are competing for use in relapsed and refractory disease - Bibliography JAPAN - Price premiums are awarded for added benefit or innovation - Pricing of launched multiple myeloma treatments - Bibliography PRICING IN THE FIVE MAJOR EU MARKETS FIVE MAJOR EU MARKETS PAYER AND KEY OPINION LEADER INSIGHTS - Insights and strategic recommendations - Real-world data are a priority for assessment bodies - Darzalex viewed as the more adaptable monoclonal antibody, but burden on hospitals could limit its potential - Kyprolis is likely to become the standard of care for recurrent disease, but its high price may pose limitations - Empliciti may face restrictions upon market entry - The majority of multiple myeloma treatment is administered in an outpatient setting - Ninlaro is an attractive oral option for elderly patients, reduces burden on ambulatory care - Farydak will experience low usage due to poor risk-benefit ratio - Pomalyst is reimbursed under a risk-sharing agreement in numerous European countries - Bibliography FRANCE GERMANY ITALY SPAIN UK For more information visit http://www.researchandmarkets.com/research/gw...le_myeloma
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Hematology
